Cargando…
Real-world data on severe lung cancer: a multicenter retrospective study
BACKGROUND: Severe lung cancer is a novel concept that describes a patient with poor performance status (PS; 2–4) but with a high probability of receiving survival benefit and improvement in the PS score. However, there is currently no relevant research or real-world data on those with severe lung c...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088003/ https://www.ncbi.nlm.nih.gov/pubmed/37057111 http://dx.doi.org/10.21037/tlcr-23-4 |
_version_ | 1785022477865320448 |
---|---|
author | Wang, Fei Xie, Xiaohong Wang, Liqiang Deng, Haiyi Wang, Qian Qi, Min Guo, Min Chen, Juan Zhou, Maolin Sun, Ni Li, Ru Yang, Yilin He, Zuer Lin, Xinqing Liu, Ming Wu, Di Sun, Gengyun Zhou, Chengzhi |
author_facet | Wang, Fei Xie, Xiaohong Wang, Liqiang Deng, Haiyi Wang, Qian Qi, Min Guo, Min Chen, Juan Zhou, Maolin Sun, Ni Li, Ru Yang, Yilin He, Zuer Lin, Xinqing Liu, Ming Wu, Di Sun, Gengyun Zhou, Chengzhi |
author_sort | Wang, Fei |
collection | PubMed |
description | BACKGROUND: Severe lung cancer is a novel concept that describes a patient with poor performance status (PS; 2–4) but with a high probability of receiving survival benefit and improvement in the PS score. However, there is currently no relevant research or real-world data on those with severe lung cancer, such as incidence, cause, clinical features, and risk factors. METHODS: The data from patients with advanced lung cancer attending multiple centers from January 1, 2022, to June 30, 2022, were collected for a cross-sectional study. In addition, data from fatal cases from January 1, 2019, to June 30, 2022, were retrospectively collected as another cohort. And we developed a questionnaire to assess clinicians’ mastery of severe lung cancer. RESULTS: Three participating institutes enrolled the data set of 1,725 patients, and the dataset of 269 fatal cases were included in another cohort; the incidence of severe lung cancer was 13.10% and 37.55%, respectively. Severe lung cancer patients were mainly stage IV elderly male patients without gene mutation and a history of resection. And the proportion of smoking and comorbidities in severe lung cancer patients is more than in non-severe lung cancer patients (50.4% vs. 40.8%, P=0.006; 46.9% vs. 36.4%, P=0.002). Treatment-related adverse events (AEs) (46.0%) accounted for the largest proportion of the primary causes of severe lung cancer in the cross-sectional study, while cancer-related symptoms (54.5%) accounted for the largest proportion of the primary causes of sever lung cancer in the 101 fatal cases. For the fatal cases, the overall survival of severe lung cancer patients caused by cancer-related symptoms was longer than that caused by treatment-related AEs (8 vs. 3 months; P=0.019). A total of 616 clinicians completed the questionnaire; 90.26% of clinicians agreed with the concept of severe lung cancer. CONCLUSIONS: The incidence of severe lung cancer cannot be ignored based on real-world data. Treatment-related AEs are gradually account for more of the causes of severe lung cancer, surpassing cancer-related symptoms and comorbidities. Furthermore, the prognosis of patients with advanced lung cancer who develop severe lung cancer due to treatment-related AEs is worse than cancer-related symptoms. |
format | Online Article Text |
id | pubmed-10088003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-100880032023-04-12 Real-world data on severe lung cancer: a multicenter retrospective study Wang, Fei Xie, Xiaohong Wang, Liqiang Deng, Haiyi Wang, Qian Qi, Min Guo, Min Chen, Juan Zhou, Maolin Sun, Ni Li, Ru Yang, Yilin He, Zuer Lin, Xinqing Liu, Ming Wu, Di Sun, Gengyun Zhou, Chengzhi Transl Lung Cancer Res Original Article BACKGROUND: Severe lung cancer is a novel concept that describes a patient with poor performance status (PS; 2–4) but with a high probability of receiving survival benefit and improvement in the PS score. However, there is currently no relevant research or real-world data on those with severe lung cancer, such as incidence, cause, clinical features, and risk factors. METHODS: The data from patients with advanced lung cancer attending multiple centers from January 1, 2022, to June 30, 2022, were collected for a cross-sectional study. In addition, data from fatal cases from January 1, 2019, to June 30, 2022, were retrospectively collected as another cohort. And we developed a questionnaire to assess clinicians’ mastery of severe lung cancer. RESULTS: Three participating institutes enrolled the data set of 1,725 patients, and the dataset of 269 fatal cases were included in another cohort; the incidence of severe lung cancer was 13.10% and 37.55%, respectively. Severe lung cancer patients were mainly stage IV elderly male patients without gene mutation and a history of resection. And the proportion of smoking and comorbidities in severe lung cancer patients is more than in non-severe lung cancer patients (50.4% vs. 40.8%, P=0.006; 46.9% vs. 36.4%, P=0.002). Treatment-related adverse events (AEs) (46.0%) accounted for the largest proportion of the primary causes of severe lung cancer in the cross-sectional study, while cancer-related symptoms (54.5%) accounted for the largest proportion of the primary causes of sever lung cancer in the 101 fatal cases. For the fatal cases, the overall survival of severe lung cancer patients caused by cancer-related symptoms was longer than that caused by treatment-related AEs (8 vs. 3 months; P=0.019). A total of 616 clinicians completed the questionnaire; 90.26% of clinicians agreed with the concept of severe lung cancer. CONCLUSIONS: The incidence of severe lung cancer cannot be ignored based on real-world data. Treatment-related AEs are gradually account for more of the causes of severe lung cancer, surpassing cancer-related symptoms and comorbidities. Furthermore, the prognosis of patients with advanced lung cancer who develop severe lung cancer due to treatment-related AEs is worse than cancer-related symptoms. AME Publishing Company 2023-03-27 2023-03-31 /pmc/articles/PMC10088003/ /pubmed/37057111 http://dx.doi.org/10.21037/tlcr-23-4 Text en 2023 Translational Lung Cancer Research. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Wang, Fei Xie, Xiaohong Wang, Liqiang Deng, Haiyi Wang, Qian Qi, Min Guo, Min Chen, Juan Zhou, Maolin Sun, Ni Li, Ru Yang, Yilin He, Zuer Lin, Xinqing Liu, Ming Wu, Di Sun, Gengyun Zhou, Chengzhi Real-world data on severe lung cancer: a multicenter retrospective study |
title | Real-world data on severe lung cancer: a multicenter retrospective study |
title_full | Real-world data on severe lung cancer: a multicenter retrospective study |
title_fullStr | Real-world data on severe lung cancer: a multicenter retrospective study |
title_full_unstemmed | Real-world data on severe lung cancer: a multicenter retrospective study |
title_short | Real-world data on severe lung cancer: a multicenter retrospective study |
title_sort | real-world data on severe lung cancer: a multicenter retrospective study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088003/ https://www.ncbi.nlm.nih.gov/pubmed/37057111 http://dx.doi.org/10.21037/tlcr-23-4 |
work_keys_str_mv | AT wangfei realworlddataonseverelungcanceramulticenterretrospectivestudy AT xiexiaohong realworlddataonseverelungcanceramulticenterretrospectivestudy AT wangliqiang realworlddataonseverelungcanceramulticenterretrospectivestudy AT denghaiyi realworlddataonseverelungcanceramulticenterretrospectivestudy AT wangqian realworlddataonseverelungcanceramulticenterretrospectivestudy AT qimin realworlddataonseverelungcanceramulticenterretrospectivestudy AT guomin realworlddataonseverelungcanceramulticenterretrospectivestudy AT chenjuan realworlddataonseverelungcanceramulticenterretrospectivestudy AT zhoumaolin realworlddataonseverelungcanceramulticenterretrospectivestudy AT sunni realworlddataonseverelungcanceramulticenterretrospectivestudy AT liru realworlddataonseverelungcanceramulticenterretrospectivestudy AT yangyilin realworlddataonseverelungcanceramulticenterretrospectivestudy AT hezuer realworlddataonseverelungcanceramulticenterretrospectivestudy AT linxinqing realworlddataonseverelungcanceramulticenterretrospectivestudy AT liuming realworlddataonseverelungcanceramulticenterretrospectivestudy AT wudi realworlddataonseverelungcanceramulticenterretrospectivestudy AT sungengyun realworlddataonseverelungcanceramulticenterretrospectivestudy AT zhouchengzhi realworlddataonseverelungcanceramulticenterretrospectivestudy |